NCT07000084
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07000084
Title Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG)
Acronym GAIN-BCG
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Alliance for Clinical Trials in Oncology
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.